Pancreatic cancer is among the most lethal cancers and the fourth leading cause of cancer deaths worldwide, where 90% of cases fall into the pancreatic ductal adenocarcinoma (PDAC) type.
EZH2 and LSD1 are histone modification enzymes often overexpressed in several types of aggressive cancer such as colorectal, breast or prostate cancer, among others.
Aberrant expression of G9a and NSD2 has been identified in multiple types of cancer. Therefore, dual-target inhibitors blocking both pathways may be considered a potential strategy to treat solid tumors. Researchers from Sun Yat-Sen University reported on the discovery and preclinical characterization of W-4032, a dual G9a/NSD2 inhibitor aimed to be used for the treatment of solid tumors.
Work at Reactive Biosciences Inc. has led to the discovery of new phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
A D3 Bio (Wuxi) Co. Ltd. patent describes heterocyclic-substituted pyrimidopyran compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Rowan University, Pennsylvania State University, and affiliated organizations presented preclinical data for the selective Mcl-1 inhibitor, KS-18, in models of multiple myeloma (MM).
Researchers from Rhodes University and collaborators identified MMV-1645152 after screening the Medicines for Malaria Venture (MMV) pandemic response box for non-cytotoxic inhibitors of Kaposi's sarcoma-associated herpesvirus (KSHV) replication.
Ono Pharmaceutical Co. Ltd. has entered into a license agreement with Ligachem Biosciences Inc. for LCB-97, a preclinical stage antibody-drug conjugate (ADC) for solid tumors.
RSS
